Vietnam’s expanding cancer diagnostics and pathology sector is creating new opportunities for immunohistochemistry as hospitals and laboratories invest in more accurate tissue-based diagnostics, biomarker testing and personalised cancer treatment.
There is currently no independently published headline valuation specifically for Vietnam’s overall Immunohistochemistry Market. However, analysis of the country’s tissue-diagnostics sector and wider Asia-Pacific IHC market indicates that Vietnam’s market could be worth approximately US$8–12 million in 2025, potentially reaching US$13–20 million by 2030, representing indicative annual growth of around 10–11%.
These figures should be regarded as an indicative market estimate rather than a published Vietnam-specific valuation.
The underlying market opportunity is increasingly clear. Vietnam’s wider Tissue Diagnostics Market reached US$24.5 million in 2025 and is projected to grow to US$39.1 million by 2034, with increasing adoption of immunohistochemistry and molecular diagnostic techniques identified as important drivers of growth.
Immunohistochemistry — commonly known as IHC — is a laboratory technique that uses antibodies to identify specific proteins or antigens within tissue samples. It allows pathologists to determine the biological characteristics of abnormal cells and plays a particularly important role in diagnosing and classifying cancer.
The market encompasses:
- Primary and secondary antibodies
- Monoclonal and polyclonal antibodies
- IHC reagents and detection systems
- Staining kits
- Automated slide stainers
- Tissue-processing technologies
- Digital pathology imaging
- Companion diagnostic assays
- Biomarker testing
- Pathology workflow software
Cancer diagnostics drives demand
Cancer represents the most important clinical application for immunohistochemistry.
Pathologists use IHC staining to identify proteins expressed within tumour tissue, helping establish the type and origin of a cancer and providing information that can influence treatment decisions.
In breast cancer, for example, testing for estrogen receptor, progesterone receptor and HER2 expression can help determine whether a patient is likely to benefit from hormone therapy or HER2-targeted medicines.
In lung cancer, colorectal cancer and other malignancies, IHC is increasingly used to detect biomarkers associated with targeted therapies and immunotherapies.
This is making IHC an important link between conventional pathology and precision oncology.
Companion diagnostics creates a higher-value market
The growth of personalised medicine is changing the role of pathology laboratories.
Rather than simply determining whether cancer is present, laboratories are increasingly required to characterise the molecular biology of a tumour and identify whether an individual patient may respond to a particular therapy.
Immunohistochemistry is one of the principal technologies supporting this shift.
Recent international approvals demonstrate the direction of the market. In 2025, new IHC companion diagnostics received regulatory approvals for biomarkers including mismatch-repair deficiency, PD-L1 and MET protein expression, enabling clinicians to identify patients who may benefit from specific targeted therapies or immunotherapies.
As more targeted oncology medicines enter clinical practice in Vietnam, demand for validated biomarker testing is likely to increase.
Digital pathology is transforming IHC workflows
Digitalisation represents another important market opportunity.
Traditionally, IHC slides are stained and examined manually through a microscope. Digital pathology allows those slides to be scanned at high resolution, stored electronically and reviewed on computer-based platforms.
Artificial intelligence can then assist pathologists in identifying tissue regions, counting cells and quantifying the intensity of biomarker staining.
This is particularly useful for tests where the proportion or intensity of positively stained tumour cells influences the clinical result.
Automation can also improve laboratory consistency. Modern IHC platforms combine automated staining, reagent management, slide tracking, digital imaging and quality control, helping high-volume pathology laboratories improve throughput and reduce variability.
Asia-Pacific IHC market exceeds US$570 million
The regional outlook reinforces Vietnam’s potential.
Grand View Research estimates that the Asia-Pacific Immunohistochemistry Market generated US$572.8 million in 2025 and is expected to reach US$1.108 billion by 2033, representing annual growth of 8.7%.
Asia-Pacific is expected to be the fastest-growing global region, supported by improving healthcare infrastructure, rising cancer incidence, higher healthcare expenditure and growing adoption of advanced diagnostic technologies.
MarketsandMarkets similarly identifies Asia-Pacific as the fastest-growing regional market and forecasts the global Immunohistochemistry Market to increase from US$3.55 billion in 2025 to approximately US$5.14 billion by 2030, at a CAGR of 7.6%.
The diagnostic segment remains the largest application, reflecting IHC’s central role in cancer pathology.
IHC increasingly connects pathology with molecular diagnostics
Immunohistochemistry is also becoming part of a broader multimodal diagnostic environment.
Advanced cancer laboratories increasingly combine IHC with PCR, fluorescence in situ hybridisation, next-generation sequencing, liquid biopsy and genomic profiling.
These technologies do not necessarily compete with one another. Instead, they can provide complementary information that helps clinicians build a more comprehensive molecular profile of a tumour.
For Vietnam, this creates opportunities across the entire laboratory workflow — from tissue processors and slide stainers to antibodies, reagents, scanners, image-analysis platforms and molecular diagnostics.
Opportunities for international suppliers
The commercial opportunity extends beyond IHC antibodies themselves.
Growth in Vietnam’s pathology infrastructure creates demand for:
- Automated slide-staining platforms
- Primary antibodies
- Detection kits and reagents
- Tissue processors and microtomes
- Digital slide scanners
- Pathology information systems
- AI-powered image analysis
- Laboratory automation
- Companion diagnostic assays
- Quality-control materials
Major global companies active in immunohistochemistry include Roche, Danaher/Leica Biosystems, Agilent Technologies, Thermo Fisher Scientific, Merck, Bio-Rad Laboratories, Cell Signaling Technology and Bio-Techne.
As Vietnam continues to strengthen cancer diagnosis, precision medicine and laboratory infrastructure, immunohistochemistry is likely to become an increasingly important component of its pathology ecosystem.
For diagnostic manufacturers, antibody and reagent suppliers, laboratory-equipment companies, digital-pathology providers and pharmaceutical companies developing targeted therapies, Vietnam represents a relatively small today but strategically important emerging market within Southeast Asia’s rapidly expanding precision-diagnostics sector.